PSC
NBIX icon

Prentiss Smith & Co’s Neurocrine Biosciences NBIX Stock Holding History

Prentiss Smith & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,763
Closed -$650K – 72
2024
Q4 		$650K Buy
+4,763
New +$589K 0.43% 48

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prentiss Smith & Co's NBIX Position: Q1 2025 in Review

Prentiss Smith & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 4,763 shares — an estimated $650K sold.

Prentiss Smith & Co first reported a position in NBIX in Q4 2024 and held it in 1 quarter. The position peaked at $650K in Q4 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Prentiss Smith & Co reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Prentiss Smith & Co sold 4,763 Neurocrine Biosciences shares in Q1 2025, an estimated $650K.
  • Prentiss Smith & Co first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 1 quarter.
  • Prentiss Smith & Co's Neurocrine Biosciences position peaked at $650K in Q4 2024.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Prentiss Smith & Co's 13F filing for Q1 2025, filed 21 Apr 2025.